MEDAN – A research team from Universitas Sumatera Utara (USU) examined the use of Hydroxyethyl Starch (HES), a type of colloid fluid used for fluid management during craniotomy procedures in adult patients. This study evaluated the potential of HES to reduce intraoperative fluid requirements while also reviewing its safety aspects, particularly regarding the risks of bleeding and impaired kidney function.
Through a systematic review and meta-analysis of 12 studies, the research team found that HES 130/0.4 has the potential to reduce the volume of fluid administered during surgery under certain protocols. However, the available scientific evidence is insufficient to establish the safety of its use in relation to various risks of complications.
The study, entitled “Perioperative Hydroxyethyl Starch Use in Adult Craniotomy: A Systematic Review and Meta-Analysis of Volume Efficiency and Safety Outcomes,” was published in the international journal Perioperative Care and Operating Room Management, Volume 44 (2026), article number 100733. The article has been available online since August 20, 2026.
The Importance of Fluid Management in Brain Surgery
Craniotomy is a surgical procedure that involves opening part of the skull to provide access to brain tissue. In this procedure, fluid management is an important aspect because it is related to maintaining blood circulation stability and the patient's physiological condition during surgery.
Appropriate fluid administration is necessary to maintain circulating volume and tissue perfusion. One type of fluid used in perioperative practice is Hydroxyethyl Starch (HES), a colloid solution that functions to expand plasma volume. Under certain conditions, HES can help reduce the volume of fluid administered compared with crystalloid solutions. Nevertheless, its use has also raised concerns because of the potential risks of acute kidney injury and bleeding. These concerns have prompted the need for further evaluation of the effectiveness and safety of HES specifically in patients undergoing craniotomy.
Reviewing 12 Studies from Various Databases
To address this issue, the research team conducted a systematic review and meta-analysis based on the PRISMA 2020 guidelines. The literature search was conducted through four scientific databases: MEDLINE/PubMed, Scopus, CENTRAL, and Web of Science, with searches conducted up to January 30, 2026.
Of the 3,650 publications identified, 12 studies met the criteria for inclusion in the main analysis. These studies consisted of eight randomized controlled trials involving a total of 371 participants and four observational studies covering more than 46,000 procedures. By combining and analyzing the results of previous studies, the research team evaluated fluid use efficiency, intraoperative blood loss, and various patient safety outcomes, including the risk of impaired kidney function.
HES Has the Potential to Reduce Intraoperative Fluid Requirements
The analysis results showed that the use of HES 130/0.4 in several goal-directed fluid therapy protocols has the potential to reduce intraoperative fluid requirements. In three of the four clinical trials reporting comparisons of fluid volumes, the reductions ranged from 240 to 1,030 mL. These findings indicate the potential for fluid volume efficiency under certain conditions and administration protocols. However, these results cannot be generalized as evidence of HES superiority for all patients or every craniotomy procedure.
Furthermore, the analysis of intraoperative blood loss did not show a clear difference between the HES and crystalloid groups. The pooled results of three clinical trials involving a total of 175 participants showed a mean difference of +36 mL, with a 95% confidence interval ranging from −80 to +152 mL. Thus, this study has not demonstrated that HES use significantly increases or decreases intraoperative blood loss compared with crystalloid fluids.
The Safety of HES Use Still Requires Further Investigation
Although it shows potential in reducing fluid requirements, the safety of HES remains a major concern. Evidence regarding the occurrence of acute kidney injury and postoperative bleeding in craniotomy patients remains limited. Among the reviewed studies, formal assessment of acute kidney injury was reported in only one small-scale clinical trial involving 60 participants, which reported no cases. This number is insufficient to establish that HES use is free from the risk of kidney dysfunction.
Meanwhile, data on postoperative hematoma from observational studies also have limitations, particularly due to the possibility of confounding factors. Based on the GRADE assessment, the certainty of evidence for several safety outcomes ranged from low to very low. These findings emphasize that fluid volume efficiency does not automatically indicate improved patient safety. Therefore, the benefits and potential risks of HES need to be assessed together before conclusions can be drawn regarding its use in brain surgery.
Encouraging Further Research for Patient Safety
Based on the findings, the research team emphasizes the need for further studies through multicenter clinical trials involving larger numbers of participants and designs that specifically consider the characteristics of craniotomy patients. Future studies should also include longer-term kidney function monitoring, for at least 30 days, as well as more comprehensive assessments of bleeding events, the need for repeat surgery due to hematoma, and patients' neurological outcomes.
These recommendations are important for obtaining stronger evidence regarding the balance between the benefits and risks of HES use. Thus, clinical decisions can be based on more adequate scientific evidence rather than solely on its potential to reduce intraoperative fluid volume.
Research Contributions to the Development of Medical Science
This publication represents a research contribution to the fields of anesthesiology and neurosurgery, highlighting the importance of implementing evidence-based medicine in healthcare services. Through a review of previous research findings, this study provides an overview of the potential for fluid efficiency as well as the limitations of evidence regarding HES safety in adult patients undergoing craniotomy.
Research Key Points
- This systematic review and meta-analysis, based on the PRISMA 2020 guidelines, examined the effectiveness and safety of Hydroxyethyl Starch (HES) use in adult patients undergoing craniotomy.
- Searches across four scientific databases up to January 30, 2026, identified 3,650 publications, of which 12 studies met the criteria for analysis.
- The 12 studies consisted of 8 randomized controlled trials involving 371 participants and 4 observational studies covering more than 46,000 procedures.
- The use of HES 130/0.4 has the potential to reduce intraoperative fluid requirements under certain protocols. In 3 of the 4 clinical trials reporting volume comparisons, fluid reductions ranged from 240 to 1,030 mL.
- An analysis of 3 clinical trials (n=175) showed no clear difference in intraoperative bleeding between the HES and crystalloid groups (MD=+36 mL; 95% CI −80 to +152; p=0.31; I²=0%).
- Evidence regarding kidney safety remains limited. Formal assessment of acute kidney injury was reported in only one small clinical trial (n=60), with no cases reported, which is insufficient to establish the safety of HES.
- Evidence regarding postoperative hematoma and other safety outcomes remains limited and may be influenced by confounding factors. The certainty of evidence based on GRADE ranged from low to very low.
- The study recommends multicenter clinical trials involving larger numbers of participants, kidney function monitoring for at least 30 days, and evaluation of bleeding, the need for repeat surgery due to hematoma, and patients' neurological outcomes.
Author
Khairul Azmi
Resource Person/Researcher
Andre Marolop Pangihutan Siahaan